144 results
424B5
PCSA
Processa Pharmaceuticals Inc
28 May 24
Prospectus supplement for primary offering
4:49pm
the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and 2022 have been audited by BD & Company, Inc., an independent registered … appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, have been audited by BD & Company, Inc., an independent
8-K
EX-4.1
kdoo2c6nfe7 b5
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
8-K
EX-10.1
095lta
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
8-K
EX-4.3
ri1mcjgv
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
8-K
EX-4.2
qgqow2swb1ueu4d3 1c
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
424B4
iuh3c us7
29 Jan 24
Prospectus supplement with pricing info
4:15pm